

BIOGRAPHICAL SKETCH

Provide the following information for the key personnel in the order listed for Form Page 2.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME		POSITION TITLE	
Norman Ilowite, M.D.		Professor of Pediatrics	
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)			
INSTITUTION AND LOCATION	DEGREE (if applicable)	YEAR(s)	FIELD OF STUDY
Rutgers College	BS	1971-75	Biochemistry
SUNY Health Sciences Center@Brooklyn	MD	1975-79	Medicine
George Washington University	PL1,2,3	1979-82	Pediatrics
University of Washington		1982-84	Rheumatology/Immunology

A. Positions and Honors.**Employment**

1996- Professor of Pediatrics, Albert Einstein College of Medicine
 1991-1996 Associate Professor of Pediatrics, Albert Einstein College of Medicine
 1991- Chief, Division of Rheumatology, Schneider Children's Hospital
 1989-1991 Assistant Professor of Pediatrics - Albert Einstein College of Medicine
 1984-1989 Assistant Professor of Pediatrics - SUNY, Health Sciences Center at Stony Brook, NY
 1984-1990 Section Head, Rheumatology, Schneider Children's Hospital

Committees/Honors

1993 Ad-hoc Center Grant Review Committee member, NIAMS, NIH
 1994-1995 President, New York Rheumatism Association
 1997-1998 Chairman, Sub-Board of Pediatric Rheumatology, American Board of Pediatrics
 1997 President, Northeast Region, American College of Rheumatology
 1998 Pediatric Rheumatology Academic Blue Ribbon Committee, ACR
 2001-2003 Program Co-Chairman: Pediatric Rheumatology 2003: Park City and Beyond
 1999-2001 Member, Workforce and Training Committee, ACR
 2000-2002 Annual Meeting Planning Committee, ACR
 2001-2002 Steering Committee, Pediatric Rheumatology Research Network
 2001-2003 American Board of Pediatrics, PMCP-S Advisory Committee
 2001- Childhood Arthritis, Rheumatology Research Association, Interim Steering Committee
 2002- American College of Rheumatology, Continuing Medical Education Committee

B. Selected peer-reviewed publications (Representative of 75 publications and 75 abstracts)

- Ilowite NT, Wedgwood RJ, Rose LM, Clark EA, Lindgren CG, Ochs HD: Impaired in vivo and in vitro antibody responses to bacteriophage ϕ X174 in juvenile rheumatoid arthritis. **J Rheumatol** 14:957-963, 1987.
- Lightman HI, Pochazvesky R, Ilowite NT: Thermography in childhood reflex sympathetic dystrophy. **J Pediatr** 111:551-555, 1987.
- Ilowite NT, Samuel P, Ginzler E, Jacobson MS: Dyslipoproteinemia in pediatric systemic lupus erythematosus. **Arthritis Rheum** 31:859-863, 1988.
- Ilowite NT, Wedgwood RJ, Valacer D, Bonagura VR: Expression of the major IgM rheumatoid factor cross-reactive idiotype precedes classic human IgG binding activity in a polyarticular juvenile rheumatoid arthritis patient. **J Rheumatol** 15:1789-1792, 1988.
- Ilowite NT, Wedgwood JF, Bonagura VR: Expression of the major rheumatoid factor cross-reactive idiotype in juvenile rheumatoid arthritis. **Arthritis Rheum** 32:265-270, 1989.
- Ilowite NT, Samuels P, Beselar L, Jacobson M: Dyslipoproteinemia in juvenile rheumatoid arthritis. **J Pediatr** 114:823-826, 1989.
- Jacobson M, Trachtman H, Samuels P, Feldman J, Ilowite NT: Dyslipoproteinemia in the NZB/NZW murine SLE model: effect of a Menhaden oil enriched diet. **Atherosclerosis** 79:205-211, 1989.
- Valacer DJ, O'Reilly ME, Ilowite NT, Bonagura VR: Identification of anti-idiotypic antibodies in the sera of rye grass allergic and non-allergic individuals. **J Allergy Clin Immunol** 88:349-55, 1991.

9. Ilowite NT, Wedgwood JF, Moore T, Ramakrishnan T, Bonagura VR: Hidden rheumatoid factor and rheumatoid factor cross reactive idiotype expression in juvenile rheumatoid arthritis. **Scand J Immunol** 34:453-460,1991.
10. Walco GA, Varni JW, Ilowite NT: Cognitive-behavioral pain management in children with juvenile rheumatoid arthritis. **Pediatrics** 89:1075-1079,1992.
11. Ilowite NT, Walco GA, Pochazchevsky R: Pain assessment in juvenile rheumatoid arthritis: the relationship between pain intensity and degree of joint inflammation. **Ann Rheum Dis** 51:343-346,1992.
12. Walco GA, Ilowite NT: Cognitive-behavioral intervention for juvenile primary fibromyalgia syndrome. **J Rheumatol** 19:1617-1619,1992.
13. Sood SK, Rubin LG, LeBlanc ME, Ilowite NT: Positive Lyme disease serology in juvenile rheumatoid arthritis in a Lyme disease endemic area: analysis by immunoblot. **J Rheumatol** 20:739-741,1993.
14. Schuval SJ, Frances A, Valderrama E, Bonagura VR, Ilowite NT: Panniculitis and fever in childhood. **J Pediatr** 122:372-378,1993.
15. Ilowite NT, Wedgwood JF, Ramakrishnan TK, Bonagura VR: Rheumatoid factor-related molecules in juvenile rheumatoid arthritis: the role of the CD5+ B cell. **Clin Immunol Immunopathol** 67:S74-82,1993.
16. Schuval SJ, Bonagura VR, Ilowite NT: Rheumatologic manifestations of human immunodeficiency virus infection in children. **J Rheumatol** 20:1578-1582, 1993.
17. Levine JJ, Sherry DD, Strickland DK, Ilowite NT: Intra-articular alpha 2 macroglobulin complexes in juvenile rheumatoid arthritis. **Pediatr Res** 34:204-207,1993.
18. Levine JJ, Ilowite NT: Scleroderma-like esophageal disease in children breast fed from mothers with breast implants. **JAMA** 271:213-216,1994.
19. Kwong T, Valderrama E, Paley C, Ilowite NT: Systemic necrotizing vasculitis associated with childhood sarcoidosis. **Sem Arth Rheum** 23:388-395,1994.
20. Kwong T, Leonides J, Ilowite NT: Asymptomatic superior vena cava obstruction and pulmonary embolism in an adolescent with SLE and antiphospholipid antibodies. **Clin Exp Rheum** 12:215-217,1994.
21. Levine JJ, Ilowite NT: Scleroderma-like esophageal disease in children of mothers with silicone breast implants. **JAMA** 272:7769-7770,1994 (letter).
22. Sood SK, Zemel LS, Ilowite NT: Criteria for positive immunoblot in pediatric Lyme arthritis. **J Rheumatol** 22:758-61,1995.
23. Ilowite NT, Copperman N, Leicht T, Kwong T, Jacobson MS: Effects of dietary modification and fish oil supplementation in dyslipoproteinemia in pediatric systemic lupus erythematosus. **J Rheumatol** 22:1347-51,1995.
24. Pettei MJ, Ilowite NT: Childhood regenerative nodular hyperplasia of the liver associated with hypoxemia. **J Pediatr Gastroenterol Nutr** 20:343-346,1995.
25. Levine JJ, Lin HC, Rowley M, Cook A, Teuber SS, Ilowite NT: Autoantibody expression in children born to mothers with silicone breast implants: lack of association with clinical symptoms. **J Pediatr** 97:243-245,1996.
26. Levine JJ, Ilowite NT, Pettei MJ, Trachtman H: Increased NO_3^- + NO_2^- and neopterin excretion in children breast fed by mothers with silicone breast implants: evidence for macrophage activation. **J Rheumatol** 23:1083-1087, 1996.
27. Gottlieb BS, Miller LC, Ilowite NT: Methotrexate treatment of Wegener's Granulomatosis in children. **J Pediatr** 129:604-607,1996.
28. Jain VK, Hilton E, Maytal J, Gerber MA, Dorante G, Ilowite NT, Sood SK: Immunoglobulin M immunoblot for diagnosis of *Borrelia burgdorferi* infection in patients with acute facial palsy. **J Clin Microbiology** 34:2033-2035, 1996.
29. Gottlieb BS, Keenan GF, Lu T, Ilowite NT: Discontinuation of methotrexate treatment in juvenile rheumatoid arthritis. **Pediatrics** 100:994-997,1997.
30. Bowyer S, Roettcher P, and the members of the Pediatric Rheumatology Database Research Group: Pediatric rheumatology clinic populations in the United States: results of a 3 year survey. **J Rheumatol** 23:1968-74, 1996.
31. Sandborg C, Wallace C, Ilowite NT et al: Position statement of the American College of Rheumatology regarding referral of children and adolescents to pediatric rheumatologists. **Arthritis Care and Research** 12:48-51,1999.
32. Cassidy JT, Athreya BH, Ilowite NT et al: The future status of pediatric rheumatology in the United States: strategic planning for the year 2000. **Arthritis Rheum** 43:239-242, 2000.
33. Degotardi P, Revenson TA, Ilowite NT: Family coping strategies, treatment compliance and psychosocial adjustment in adolescents with JRA. **Arthritis Care and Research** 12:314-324,1999.
34. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, Stein LD, Gedalia A, Ilowite NT, Wallace CA, Whitmore J, Finck BK: Etanercept in children with polyarticular juvenile rheumatoid arthritis. **N Engl J Med**. 2000 Mar 16;342(11):763-9.
35. Ilowite NT. Current treatment of Juvenile Rheumatoid Arthritis. **Pediatrics** 2002;109:109-115
36. Milojevic D, Ilowite NT. Treatment of rheumatic diseases in children: special considerations. **Rheum Dis Clinics N Amer**, in press.
37. Eberhard A, Ilowite NT: Lipodystrophy and panniculitis. **Current Opinion Rheum**, in press

C. Research Support. List selected ongoing or completed (during the last three years, research projects (federal and non-federal support). Begin with the projects that are most relevant to the research proposed in this application. Briefly indicate the overall goals of the projects and responsibilities of principal investigator identified above.

ONGOING

2001-2003 (5% effort)
— /per patient

Industry Sponsored
A 12-week double-blind randomized trial with a 12-week open-label extension to investigate the efficacy and safety of novel agent administered once daily and naproxen oral suspension administered twice daily in children with juvenile rheumatoid arthritis.

1997-2003 (5% effort)
—

Industry sponsored
Safety, population pharmacokinetics and efficacy of a novel agent in the treatment of JRA

2000-2002 (5% effort)
— /per patient

Industry sponsored
Randomized, multicenter, blinded, placebo-controlled study with an open label run in period to evaluate the efficacy, safety, and pharmacokinetics of a novel agent in polyarticular course juvenile rheumatoid arthritis

2000-2002 (5% effort)
— /per patient

Industry sponsored
Companion study to evaluate the long term safety of a novel agent in polyarticular course juvenile rheumatoid arthritis.

2000-2005 (10% effort)
— /per patient

Industry sponsored
Phase IV registry of a novel agent in juvenile rheumatoid arthritis.

2000-2002 (5% effort)
— /per patient

Industry sponsored
Phase III double-blind, randomized study comparing methotrexate plus a novel agent vs. methotrexate alone in polyarticular course JRA

COMPLETED

1996-1999 (5% effort)
—

Industry sponsored
Pharmacokinetics, safety and efficacy of TNFR:Fc in the treatment of methotrexate resistant polyarticular juvenile rheumatoid arthritis.

1999-2001 (5% effort)
— /per patient

Industry Sponsored
Open, oral dose study to evaluate the steady-state plasma concentration profile of a novel agent, followed by a 12 week, double-blind, active comparator-controlled extension in late and post-pubertal adolescents with JRA.

1999-2000 (5% effort)
—

Industry sponsored
Open label study of a NSAID in patients with JRA